Abstract
Background
Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients.
Methods
70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5).
Results
In these patients [65.7 % male, age 41 ± 9 years, mGFR 74 ± 27 mL/min/1.73 m2 and TKV 1.92 (1.27–2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p < 0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4).
Conclusions
Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.
References
Neumann HP, Jilg C, Bacher J, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28:1472–87.
Higashihara E, Nutahara K, Kojima M, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421–7.
Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359:1477–85.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.
van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol. 1999;10(9):1958–64.
Hora M, Reischig T, Hes O, et al. Urological complications of congenital nephrogenic diabetes insipidus—long-term follow-up of one patient. Int Urol Nephrol. 2006;38:531–2.
Higuchi A, Kawamura T, Nakai H, et al. Infrequent voiding in nephrogenic diabetes insipidus as a cause of renal failure. Pediatr Int. 2002;44:540–2.
Korzets A, Sachs D, Gremitsky A, et al. Unexplained polyuria and non-obstructive hydronephrosis in a urological department. Nephrol Dial Transplant. 2004;19:2410–2.
Harrison RB, Ramchandani P, Allen JT. Psychogenic polydipsia: unusual cause for hydronephrosis. AJR Am J Roentgenol. 1979;133:327–8.
Maroz N, Maroz U, Iqbal S, et al. Nonobstructive hydronephrosis due to social polydipsia: a case report. J Med Case Rep. 2012;6:376–8.
Singh H, Linas SL. Compulsive water drinking in the setting of anticholinergic drug use: an unrecognized cause of chronic renal failure. Am J Kidney Dis. 1995;26:586–9.
Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3–4 Study. Am J Kidney Dis. 2011;57:692–9.
Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013;84:1278–86.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
Donker AJ, van der Hem GK, Sluiter WJ, et al. A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med. 1977;20:97–103.
Apperloo AJ, de Zeeuw D, Donker AJ, et al. Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. J Am Soc Nephrol. 1996;7:567–72.
Bae KT, Commean PK, Lee J. Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr. 2000;24:614–9.
Masselli G, Derme M, Laghi F, et al. Imaging of stone disease in pregnancy. Abdom Imaging. 2013;38:1409–14.
Blomlie V, Rofstad EK, Trope C, Lien HH. Critical soft tissues of the female pelvis: serial MR imaging before, during, and after radiation therapy. Radiology. 1997;203:391–7.
Verswijvel GA, Oyen RH, Van Poppel HP, et al. Magnetic resonance imaging in the assessment of urologic disease: an all-in-one approach. Eur Radiol. 2000;10:1614–9.
Bhargava P, Dighe MK, Lee JH, Wang C. Multimodality imaging of ureteric disease. Radiol Clin N Am. 2012;50:271–99.
Spiro FI, Fry IK. Ureteric dilatation in nonpregnant women. Proc R Soc Med. 1970;63:462–6.
Zelenko N, Coll D, Rosenfeld AT, et al. Normal ureter size on unenhanced helical CT. AJR Am J Roentgenol. 2004;182:1039–41.
Blum A, Friedland GW. Urinary tract abnormalities due to chronic psychogenic polydipsia. Am J Psychiatry. 1983;140:915–6.
Weber M, Berglund D, Reule S, et al. Daily fluid intake and outcomes in kidney recipients: post hoc analysis from the randomized ABCAN trial. Clin Transplant. 2015;29:261–7.
Zermann DH, Loffler U, Reichelt O, et al. Bladder dysfunction and end stage renal disease. Int Urol Nephrol. 2003;35:93–7.
Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1140–50.
European Medicines Agency. Summary of medicinal product characteristics Jinarc. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002788/WC500187921.pdf. Accessed 10 Nov 2015.
Jin XD, Chen ZD, Cai SL, et al. Nephrogenic diabetes insipidus with dilatation of bilateral renal pelvis, ureter and bladder. Scand J Urol Nephrol. 2009;43:73–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no conflict of interest exists.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number METc2006.285, METc2010.173 and METc2010.187) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Casteleijn, N.F., Messchendorp, A.L., Bae, K.T. et al. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clin Exp Nephrol 21, 375–382 (2017). https://doi.org/10.1007/s10157-016-1297-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-016-1297-1